We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+61.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$936M
AUM Growth
+$589M
(+170%)
Cap. Flow
+$339M
Cap. Flow
% of AUM
36.25%
Top 10 Holdings %
Top 10 Hldgs %
80.61%
Holding
67
New
28
Increased
19
Reduced
5
Closed
15
Top Buys
| 1 |
Dianthus Therapeutics
DNTH
|
+$122M |
| 2 |
Perspective Therapeutics
CATX
|
+$37.6M |
| 3 |
ORKA
Oruka Therapeutics
ORKA
|
+$29.9M |
| 4 |
JBIO
Jade Biosciences
JBIO
|
+$20.3M |
| 5 |
Enliven Therapeutics
ELVN
|
+$18.3M |
Top Sells
| 1 |
CG Oncology
CGON
|
+$10.4M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$8.35M |
| 3 |
McKesson
MCK
|
+$7.81M |
| 4 |
Agilent Technologies
A
|
+$5.65M |
| 5 |
Pfizer
PFE
|
+$5.07M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Consumer Staples | 0.39% |
| 3 | Consumer Discretionary | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Icon
ICLR
$13.3B
| $3.66M | 0.39% |
32,000
-1,100
| -3% | -$150K |
|
27
Natera
NTRA
$39.7B
| $3.66M | 0.39% |
18,000
+6,200
| +53% | +$1.33M |
|
28
Structure Therapeutics
GPCR
$3.53B
| $3.44M | 0.37% |
+78,000
| New | +$5.34M |
|
29
Corvus Pharmaceuticals
CRVS
$1.25B
| $3.43M | 0.37% |
+230,000
| New | +$3.67M |
|
30
Hims & Hers Health
HIMS
$8.6B
| $2.92M | 0.31% |
+125,000
| New | +$2.95M |
|
31
Genmab
GMAB
$17.9B
| $2.67M | 0.29% |
100,000
+8,000
| +9% | +$240K |
|
32
Corcept Therapeutics
CORT
$9.62B
| $2.6M | 0.28% |
60,000
+38,000
| +173% | +$1.42M |
|
33
Centene
CNC
$32.9B
| $2.29M | 0.24% |
70,000
-49,400
| -41% | -$2.03M |
|
34
Intellia Therapeutics
NTLA
$1.82B
| $1.97M | 0.21% |
+150,000
| New | +$1.91M |
|
35
Peloton Interactive
PTON
$2.74B
| $1.95M | 0.21% |
+400,000
| New | +$1.95M |
|
36
ODDITY Tech
ODD
$804M
| $1.94M | 0.21% |
+140,000
| New | +$3.51M |
|
|
AVR
37
Anteris Technologies
AVR
$846M
| $1.75M | 0.19% |
+300,000
| New | +$1.72M |
|
38
MoonLake Immunotherapeutics
MLTX
$1.67B
| $1.75M | 0.19% |
+100,000
| New | +$1.66M |
|
39
Kenvue
KVUE
$35.9B
| $1.72M | 0.18% |
100,000
-132,800
| -57% | -$2.37M |
|
40
Insulet
PODD
$11B
| $1.72M | 0.18% |
+10,000
| New | +$2.51M |
|
41
Charles River Laboratories
CRL
$11B
| $1.67M | 0.18% |
+10,000
| New | +$1.85M |
|
42
Revolution Medicines
RVMD
$39.2B
| $1.46M | 0.16% |
+15,000
| New | +$1.51M |
|
|
ABVX
43
Abivax
ABVX
$11.9B
| $1.11M | 0.12% |
+10,000
| New | +$1.18M |
|
44
Arbutus Biopharma
ABUS
$901M
| $1.09M | 0.12% |
+250,000
| New | +$1.09M |
|
45
UnitedHealth
UNH
$380B
| $1.03M | 0.11% |
+3,800
| New | +$1.13M |
|
46
Abbott
ABT
$155B
| $908K | 0.1% |
+10,000
| New | +$1.13M |
|
|
BBOT
47
BridgeBio Oncology
BBOT
$674M
| $761K | 0.08% |
+87,706
| New | +$942K |
|
48
BridgeBio Pharma
BBIO
$16.2B
| $711K | 0.08% |
+10,000
| New | +$725K |
|
49
Acadia Pharmaceuticals
ACAD
$4.44B
| $580K | 0.06% |
25,934
-80,966
| -76% | -$1.93M |
|
50
Legend Biotech
LEGN
$4.46B
| $353K | 0.04% |
+15,000
| New | +$286K |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH